Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Clin Pediatr Dent ; 17(Suppl 1): S55-S60, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-39185264

RESUMO

Objective: To enhance the survival rate of atraumatic restorative treatment (ART) restorations using (class I and class II) bilayer technique of placing glass ionomer cement (GIC) along with nanofilled coating (NC) over the restorations, thereby improving longevity. Study design: A total of 178 primary molars in 67 children were selected and randomly divided into four groups. Group IA was treated with a single layer of GIC, followed by a protective layer of petroleum jelly in class I restoration. Group IB was treated with a single layer of GIC, followed by a protective layer of petroleum jelly in class II restoration. Group IIA was treated with bilayer GIC restoration followed by NC of GC-Coat Plus in class I, whereas group IIB was treated with bilayer GIC restoration followed by GC-Coat Plus in class II. Clinical analysis of all three groups was performed at 1, 3, 6, 9, and 12 months to evaluate the success of treatment procedures using predetermined criteria. Pearson's Chi-square and Kaplan-Meier estimates were utilized to evaluate the success of all four treatment procedures (p < 0.05). Results: Out of 178 teeth, 33 teeth were in group IA, 36 teeth were in group IB, 43 teeth were in group IIA, and 40 teeth were available for evaluation at the end of the 12-month follow-up period. The overall success was determined to be 81% for group IA, 79.2% for group IB, 79.5% for group IIA, and 88.6% for IIB. At 6th-month follow-up, one clinical failure was observed in groups IA and IB. At 9 months follow-up, two clinical failures were observed in both group IA and group IB and three failures were observed in group IIB. At 12 months follow-up, four clinical failures were observed in group IA, three in group IB and one clinical failure was observed in group IIB. There was no statistically significant difference observed between the success of the four groups, suggesting that either of the techniques can be utilized for ART. Conclusion: No statistically significant difference was observed between the survival of class I and class II restorations of both the groups, indicating that either single-layer or bilayer technique along with NC can be adopted for the management of dental caries in primary molars using the ART approach. How to cite this article: Khan N, Garg N, Garg N, et al. Comparative Evaluation of the Survival Rates of Atraumatic Restorative Treatment Restorations Using Bilayer Technique along with Nanofilled Coating in Primary Molars: A Clinical Study. Int J Clin Pediatr Dent 2024;17(S-1):S55-S60.

2.
Sci Rep ; 14(1): 20205, 2024 08 30.
Artigo em Inglês | MEDLINE | ID: mdl-39215007

RESUMO

This retrospective cohort study aims to describe the clinical characteristics and outcomes and assess risk factors for mortality across the epidemic waves in hospitalized COVID-19 patients in a major tertiary-care center in Pakistan. A total of 5368 patients with COVID-19, hospitalized between March 2020 and April 2022 were included. The median age was 58 years (IQR: 44-69), 41% were females, and the overall mortality was 12%. Comparative analysis of COVID-19 waves showed that the proportion of patients aged ≥ 60 years was highest during the post-wave 4 period (61.4%) and Wave 4 (Delta) (50%) (p < 0.001). Male predominance decreased from 65.2% in Wave 2 to 44.2% in Wave 5 (Omicron) (p < 0.001). Mortality rate was lowest at 9.4% in wave 5 and highest at 21.6% in the post-wave 4 period (p = 0.041). In multivariable analysis for risk factors of mortality, acute respiratory distress syndrome (ARDS) was most strongly associated with mortality (aOR 22.98, 95% CI 15.28-34.55, p < 0.001), followed by need for mechanical ventilation (aOR 6.81, 95% CI 5.13-9.05, p < 0.001). Other significant risk factors included acute kidney injury (aOR 3.05, 95% CI 2.38-3.91, p < 0.001), stroke (aOR 2.40, 95% CI 1.26-4.60, p = 0.008), pulmonary embolism (OR 2.07, 95% CI 1.28-3.35, p = 0.003), and age ≥ 60 years (aOR 2.45, 95% CI 1.95-3.09, p < 0.001). Enoxaparin use was associated with lower mortality odds (aOR 0.45, 95% CI 0.35-0.60, p < 0.001. Patients hospitalized during Wave 4 (aOR 2.22, 95% CI 1.39-3.56, p < 0.001) and the post-wave 4 period (aOR 2.82, 95% CI 1.37-5.80, p = 0.005) had higher mortality odds compared to other waves. The study identifies higher mortality risk in patients admitted in Delta wave and post-wave, aged ≥ 60 years, and with respiratory and renal complications, and lower risk with anticoagulation during COVID-19 waves.


Assuntos
COVID-19 , Mortalidade Hospitalar , Hospitalização , Humanos , COVID-19/mortalidade , COVID-19/epidemiologia , Masculino , Feminino , Pessoa de Meia-Idade , Paquistão/epidemiologia , Fatores de Risco , Idoso , Estudos Retrospectivos , Adulto , Respiração Artificial , SARS-CoV-2/isolamento & purificação , Síndrome do Desconforto Respiratório/mortalidade , Centros de Atenção Terciária/estatística & dados numéricos
3.
Artif Organs ; 48(7): 763-770, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38234162

RESUMO

BACKGROUND: Although acute kidney injury (AKI) has been established as an independent risk factor for in-hospital mortality for patients on veno-arterial (V-A) extracorporeal membranous oxygenation (ECMO), the impact of Kidney Disease Improving Global Outcomes (KDIGO) stages of AKI has yet to be elucidated as a risk factor. METHODS: We conducted a retrospective analysis of patient outcomes based on KDIGO stages of AKI at a single institution. The analysis was a cohort of 179 patients; 66 without AKI, 19 with stage 1 AKI, 18 with stage 2 AKI, and 76 with stage 3 AKI. RESULTS: Every 1-year increase in age was associated with 4% increased odds of mortality at 30 days (95% confidence interval [CI] 1.01, 1.07; p = 0.004). The presence of AKI at any stage was associated with 59% increased odds of 30-day mortality (95% CI 0.81, 3.10; p = 0.176). The presence of stage 1 AKI was associated with a 5% decreased odds of 30-day mortality (95% CI 0.32, 2.89). The presence of stage 2 AKI (odds ratio [OR] 2.29, 95% CI 0.69, 7.55; p = 0.173) and stage 3 AKI (OR 1.68, 95% CI 0.81, 3.46; p = 0.164) was associated with increased odds of 30-day mortality. CONCLUSION: Based on our single-center study, higher KDIGO stages of AKI likely have increased odds of mortality at 30 days. Larger studies are needed to confirm these findings.


Assuntos
Injúria Renal Aguda , Oxigenação por Membrana Extracorpórea , Mortalidade Hospitalar , Humanos , Oxigenação por Membrana Extracorpórea/métodos , Oxigenação por Membrana Extracorpórea/efeitos adversos , Injúria Renal Aguda/terapia , Injúria Renal Aguda/mortalidade , Masculino , Estudos Retrospectivos , Feminino , Pessoa de Meia-Idade , Fatores de Risco , Idoso , Resultado do Tratamento , Adulto , Índice de Gravidade de Doença
4.
Phytochem Rev ; : 1-16, 2023 Jun 08.
Artigo em Inglês | MEDLINE | ID: mdl-37359710

RESUMO

Chimaphila umbellata has been studied for almost two centuries now, with the first paper exploring the phytochemistry of the plant published in 1860. Almost all contemporary studies focus on the biotechnological advances of C. umbellata including its utilization as a natural alternative in the cosmetic, food, biofuel, and healthcare industry, with a special focus on its therapeutic uses. This literature review critically investigates the significance and applications of secondary metabolites extracted from the plant and presses on the biotechnological approaches to improve its utilization. C. umbellata is home to many industrially and medicinally important phytochemicals, the majority of which belong to phenolics, sterols, and triterpenoids. Other important compounds include 5-hydroxymethylfurfural, isohomoarbutin, and methyl salicylate (the only essential oil of the plant). Chimaphilin is the characteristic phytochemical of the plant. This review focuses on the phytochemistry of C. umbellata and digs into their chemical structures and attributes. It further discusses the challenges of working with C. umbellata including its alarming conservation status, problems with in-vitro cultivation, and research and development issues. This review concludes with recommendations based on biotechnology, bioinformatics, and their crucial interface.

5.
PLoS One ; 17(1): e0262608, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35085312

RESUMO

The pharmacological management of COVID-19 has evolved significantly and various immunomodulatory agents have been repurposed. However, the clinical efficacy has been variable and a search for cure for COVID-19 continues. A retrospective cohort study was conducted on 916 patients hospitalized with polymerase chain reaction (PCR)-confirmed COVID-19 between February 2020 and October 2020 at a tertiary care academic medical center in Karachi, Pakistan. The median age was 57 years (interquartile range (IQR) 46-66 years). The most common medications administered were Methylprednisolone (65.83%), Azithromycin (50.66%), and Dexamethasone (46.6%). Majority of the patients (70%) had at least two or more medications used in combination and the most frequent combination was methylprednisolone with azithromycin. Overall in-hospital mortality was 13.65% of patients. Mortality was found to be independently associated with age greater than or equal to 60 years (OR = 4.98; 95%CI: 2.78-8.91), critical illness on admission (OR = 13.75; 95%CI: 7.27-25.99), use of hydrocortisone (OR = 12.56; 95%CI: 6.93-22.7), Ferritin> = 1500(OR = 2.07; 95%CI: 1.18-3.62), Creatinine(OR = 2.33; 95%CI: 1.31-4.14) and D-Dimer> = 1.5 (OR = 2.27; 95%CI: 1.26-4.07). None of the medications whether used as monotherapy or in combination were found to have a mortality benefit. Our study highlights the desperate need for an effective drug for the management of critical COVID-19 which necessitates usage of multiple drug combinations in patients particularly Azithromycin which has long term implications for antibiotic resistance particularly in low-middle income countries.


Assuntos
COVID-19/mortalidade , COVID-19/terapia , Imunomodulação/fisiologia , Idoso , Azitromicina/uso terapêutico , COVID-19/epidemiologia , Estudos de Coortes , Dexametasona/uso terapêutico , Feminino , Mortalidade Hospitalar , Hospitalização , Humanos , Agentes de Imunomodulação/uso terapêutico , Masculino , Metilprednisolona/uso terapêutico , Pessoa de Meia-Idade , Paquistão/epidemiologia , Estudos Retrospectivos , SARS-CoV-2/patogenicidade , Atenção Terciária à Saúde/métodos , Resultado do Tratamento
6.
J Infect Dev Ctries ; 15(4): 480-489, 2021 04 30.
Artigo em Inglês | MEDLINE | ID: mdl-33956647

RESUMO

INTRODUCTION: Limited data exist on clinical characteristics and outcomes of hospitalized COVID-19 patients in low-middle income countries. We aimed to describe the clinical spectrum and outcomes of hospitalized COVID-19 patients at a tertiary-care center in Karachi, Pakistan. METHODOLOGY: We conducted an observational study of adult COVID-19 patients hospitalized between February-June 2020. Patients with a discharge diagnosis of COVID-19 and PCR positivity were included. We created logistic regression models to understand association of clinical characteristics with illness severity and in-hospital mortality. RESULTS: The study population comprised 445 patients [67% males, median age 53 (IQR 40-64) years]. Majority of patients (N = 268; 60%) had ≥ 1 co-morbid [37.5% hypertension, 36.4% diabetes]. In-hospital mortality was 13%. Age ≥ 60 (aOR] =1.92; 95 %CI = 1.23-3.03), shortness of breath (aOR=4.43; 95% CI=2.73-7.22), CRP ≥150mg/L (aOR:1.77; 95% CI=1.09-2.85), LDH ≥ 500 I.U/L (aOR:1.98; 95% CI=1.25-3.16), Neutrophil-to-Lymphocyte ratio (NLR) ≥5 (aOR:2.80; 95%CI = 1.77-4.42) and increase in serum creatinine (aOR:1.32; 95%CI=1.07-1.61) were independently associated with disease severity. Septic shock (aOR: 13.27; 95% CI=3.78-46.65), age ≥ 60 (aOR: 3.26; 95% CI=1.07-9.89), Ferritin ≥ 1500ng/ml (aOR: 3.78; 95% CI=1.21-11.8), NLR ≥ 5 (aOR: 4.04; 95% CI=1.14-14.35) and acute kidney injury (aOR: 5.52; 95% CI=1.78-17.06) were independent predictors of in-hospital mortality. CONCLUSIONS: We found multiple predictors to be independently associated with in-hospital mortality, except diabetes and gender. Compared to reports from other countries, the in-hospital mortality among COVID-19 patients was lower, despite a high burden of co-morbidities. Further research is required to explore reasons behind this dichotomy.


Assuntos
COVID-19/etiologia , COVID-19/terapia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , COVID-19/diagnóstico por imagem , Teste de Ácido Nucleico para COVID-19 , Portador Sadio , Cuidados Críticos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Paquistão , Respiração Artificial , Índice de Gravidade de Doença , Esteroides/uso terapêutico , Centros de Atenção Terciária , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA